Dachman v. United States

73 Fed. Cl. 508, 2006 U.S. Claims LEXIS 294, 2006 WL 2848616
CourtUnited States Court of Federal Claims
DecidedOctober 4, 2006
DocketNo. 05-772C
StatusPublished
Cited by3 cases

This text of 73 Fed. Cl. 508 (Dachman v. United States) is published on Counsel Stack Legal Research, covering United States Court of Federal Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dachman v. United States, 73 Fed. Cl. 508, 2006 U.S. Claims LEXIS 294, 2006 WL 2848616 (uscfc 2006).

Opinion

OPINION

HORN, Judge.

FINDINGS OF FACT

Plaintiff, Sarah R. Dachman, a medical doctor, is a former employee of the Food and Drug Administration (FDA), an agency in the Department of Health and Human Services (HHS). In July, 1988, plaintiff began employment with the defendant and signed her first “Agreement to Receive an Allowance Under the Federal Physicians Comparability Allowance [PCA] Program,” pursuant to 5 U.S.C. § 5948 (2000).1 Beginning in July, 1994, and continuing until Dr. Daehman’s removal from the FDA, plaintiff and her employer had disagreements regarding her time, attendance and performance. Plaintiff alleges that in July, 1994, her super[510]*510visor, Dr. William Schwieterman, wrongfully accused plaintiff of leaving a threatening message on her supervisor’s voice mail. Plaintiff states she was arrested for leaving the threatening message, but that criminal charges were later dismissed. Plaintiff alleges that these wrongful actions led to her placement on administrative leave with pay and the agency’s proposal to suspend her. Plaintiff further alleges that even after she demonstrated, through voice analysis, that she did not leave any threatening message, “[o]ver the next 3 years the Agency continued pursuing Dr. Dachman, reassigning [her] to a section for which she did not have adequate specialty training, refusing to let her go on a detail to a division that wanted her, placing her and her children under surveillance at their home, suspending her again, placing her on leave restriction, which made it arduous to get religious compensatory time ... and ultimately terminating her in February of 1998.”

The record reflects that the plaintiff was informed by agency memorandum dated September 23,1997 that she was placed in a non-duty status, with pay (administrative leave), for inappropriate and unacceptable conduct at work.2 Plaintiff was given several instructions as a condition of her status, including requirements to check in by telephone every day at 10:00 a.m., to remain available to the Agency, and to submit requests for leave. Plaintiff was informed that if she failed to follow these instructions, she would be charged Absent Without Leave (AWOL) for the period of unavailability.

Plaintiff signed her last PCA Agreement, which is the one at issue in this litigation, on September 27, 1996. Subdivision 6 of this PCA agreement stated:

(b) That in the event I voluntarily or because of misconduct fail to complete the second year of a two-year agreement in a position which entitled me to receive the allowance, I will refund the amount of the allowance I received under this agreement for the 26 weeks of service immediately preceding the termination unless the Assistant Secretary for Health determines that my failure to complete my agreed period of service is due to circumstances which are beyond my control.
(c) It is further agreed that any amount which I am obligated to refund under (a) or (b) of this paragraph will be a debt due to the United States which I hereby agree to pay in full as directed by the Department of Health and Human Services.

Dr. Patricia Keegan, Chief, Oncology Branch, Center for Biologic Evaluation and Research, FDA, scheduled a meeting with the plaintiff for September 29, 1997, at 2:00 p.m., to discuss work issues. At the September 29, 1997, 2:00 p.m. meeting, Dr. Keegan had planned to issue plaintiff a memorandum proposing her removal from the FDA based on “longstanding and repeated misconduct.” When the plaintiff failed to report for duty, the memorandum was delivered by mail and Federal Express to the plaintiffs home, and her employment status was classified as AWOL until she appeared for work on assigned tasks, after which she would be placed on administrative leave with pay and required to follow instructions in the memorandum.

Dr. Keegan’s memorandum indicated that the agency proposed to remove her from federal service for “(1) Repeated Failure to Follow Supervisory Instructions, (2) Repeated Unauthorized Absences, (3) Unacceptable Conduct, and (4) Misuse of Government Equipment.” Over the course of a lengthy memorandum, numerous examples were cited, by specific date, of plaintiffs conduct which the agency indicated led to the proposed removal. Dr. Keegan’s memorandum notified plaintiff that “you will continue in a non-duty status with pay (administrative leave) at your present grade and salary during the advance notice period of this action.” Dr. Keegan also repeated the instructions that plaintiff must check in by telephone and remain available during her normal work day, with the reminder that, “[i]f you fail to [511]*511do so and are unavailable when needed or summoned, you will be charged AWOL for the period of unavailability.”

Two days later, Dr. Keegan sent a second memorandum to plaintiff, dated October 1, 1997, which explained in detail why her status had been changed to AWOL after she had missed the September 29,1997, 2:00 p.m. meeting, and again informed plaintiff that, “you will remain on AWOL status until you come in to work on these tasks,” referring to the instructions in the earlier memorandum.

On February 5,1998, Dr. David W. Feigal, Deputy Director, Center for Biologies Evaluation and Research, FDA, sent plaintiff a twenty-two page memorandum reiterating the agency’s reasons for deciding to remove plaintiff, including her repeated unauthorized absences, unacceptable conduct, failure to adhere to agency instructions, and misuse of government equipment. In the memorandum, Dr. Feigal confirmed the agency decision to remove plaintiff, effective February 6, 1998. Dr. Feigal’s February 5, 1998 memorandum also explained to the plaintiff that she had the right to appeal the termination decision to the Regional Director of the Merit Systems Protection Board (MSPB), or that, for allegations of discrimination, plaintiff could file a complaint with HHS in accordance with the Equal Employment Opportunity Commission (EEOC) regulations.

On February 6, 1998, HHS issued a “Notification of Personnel Action” to remove the plaintiff for “repeated failure to follow supervisory instruction and unauthorized absences and unacceptable conduct and misuses of government equipment.” This form also notified plaintiff that “the employee is obligated to pay debt for noneompletion of a PCA contract. The debt is approximately $7,995.00.”

Because the plaintiff had not fully satisfied the debt, on June 18,1999, the Debt Management Branch sent plaintiff a notice stating that “an overpayment that incurred while you were employed with the Department of Health and Human Services is still outstanding____ This debt must be paid within 30 days from the date of this letter----” The “Nature of Debt” was listed as “Physicians Comp. Pay” and the amount indicated was “$2,973.04.” The Debt Management Branch also sent plaintiff a separate notice on June 18, 1999, that an overpayment in the amount of $1,116.82 had occurred in plaintiffs Base Pay from December 23, 1995 — February 3, 1996, and that she must repay the debt within 30 days, or interest would accrue on the unpaid principal balance. According to a letter from the HHS Chief of the Debt Collection Center dated July 19, 2005 and attached to the complaint, not until more than five years later, on July 13, 2004, was the remaining debt paid by plaintiff in full, $1,595.75 for overpaid base pay plus interest, and $4,976.34 for PCA debt plus interest.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hall v. United States
617 F.3d 1313 (Federal Circuit, 2010)
Hall v. United States
89 Fed. Cl. 102 (Federal Claims, 2009)
Dachman v. United States
230 F. App'x 981 (Federal Circuit, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
73 Fed. Cl. 508, 2006 U.S. Claims LEXIS 294, 2006 WL 2848616, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dachman-v-united-states-uscfc-2006.